PT - JOURNAL ARTICLE AU - Sandile Cele AU - Farina Karim AU - Gila Lustig AU - James Emmanuel San AU - Tandile Hermanus AU - Houriiyah Tegally AU - Jumari Snyman AU - Thandeka Moyo-Gwete AU - Eduan Wilkinson AU - Mallory Bernstein AU - Khadija Khan AU - Shi-Hsia Hwa AU - Sasha W. Tilles AU - Lavanya Singh AU - Jennifer Giandhari AU - Ntombifuthi Mthabela AU - Matilda Mazibuko AU - Yashica Ganga AU - Bernadett I. Gosnell AU - Salim Abdool Karim AU - Willem Hanekom AU - Wesley C. Van Voorhis AU - Thumbi Ndung’u AU - COMMIT-KZN Team AU - Richard J. Lessells AU - Penny L. Moore AU - Mahomed-Yunus S. Moosa AU - Tulio de Oliveira AU - Alex Sigal TI - SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity AID - 10.1101/2021.09.14.21263564 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.14.21263564 4099 - http://medrxiv.org/content/early/2021/12/07/2021.09.14.21263564.short 4100 - http://medrxiv.org/content/early/2021/12/07/2021.09.14.21263564.full AB - Characterizing SARS-CoV-2 evolution in specific geographies may help predict the properties of variants coming from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from the ancestral virus in a person with advanced HIV disease. Infection was before the emergence of the Beta variant first identified in South Africa, and the Delta variant. We compared early and late evolved virus to the ancestral, Beta, Alpha, and Delta viruses and tested against convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, whereas late virus was similar to Beta, exhibiting vaccine escape and, despite pre-dating Delta, strong escape of Delta-elicited neutralization. This example is consistent with the notion that variants arising in immune-compromised hosts, including those with advanced HIV disease, may evolve immune escape of vaccines and enhanced escape of Delta immunity, with implications for vaccine breakthrough and reinfections.HighlightsA prolonged ancestral SARS-CoV-2 infection pre-dating the emergence of Beta and Delta resulted in evolution of a Beta-like serological phenotypeSerological phenotype includes strong escape from Delta infection elicited immunity, intermediate escape from ancestral virus immunity, and weak escape from Beta immunityEvolved virus showed substantial but incomplete escape from antibodies elicited by BNT162b2 vaccinationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), South African Medical Research Council awards (AS, TdO, PLM) and National Institutes of Health U01 AI151698 (WVV). PLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nasopharyngeal and oropharyngeal swab samples and plasma samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu Natal (reference BREC/00001275/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available in the manuscript, GISAID SARS-CoV-2 sequence repository, or upon reasonable request from the authors. https://www.gisaid.org/